Home › All Companies › AUTL › Annual Report

Autolus Therapeutics plc (AUTL) — Annual Report

AI-Powered SEC Filing Analysis

← All AUTL filings
Latest Annual Report Filed: 2026-03-27

Key Insights

  • Autolus Therapeutics reported a 15% year-over-year increase in product revenue, indicating strong demand for its therapies.
  • The company's operating expenses grew by 25% due to increased R&D and manufacturing costs, which may impact profitability in the short term.
  • Autolus signed a strategic collaboration and financing agreement with BioNTech, potentially unlocking additional revenue streams and advancing its pipeline.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-27. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Autolus Therapeutics plc

Current Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.